real-time news and commentary for investors
Tuesday, Oct 15
Insmed rises after completing enrollment in Arikace NTM trial
- Insmed (INSM +9.9%) rallies after saying it has completed enrollment in a Phase 2 Arikace study for NTM patients.
- The company also says it has commenced the SAWP process with the EMA and will discuss Arikace and NTM with the agency in Q4.
- Due to the challenge associated with enrolling patients who have had six months of ATS/IDSA guideline therapy, "completing enrollment ... is a major accomplishment," the company notes. (PR)
- Some analysts, including UBS' Matthew Harrison and Leerink's Joseph Schwartz think NTM is where the drug's true potential lies, despite CF trials.